🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CR rate with Cretostimogene Grenadenorepvec for High-Risk BCG- Unresponsive NMIBC with CIS in BOND-003. #MedIQAUA25 #AUA25 #bladdercancer Mark Tyson

FIRST RESULTS! SUNRISE 1 COHORT 4 - TAR-200 monotherapy in papillary disease only HR NMIBC #MedIQAUA25 #AUA25 #bladdercancer Bladder Cancer Advocacy Network Félix Guerrero-Ramos

Thrilled to share the pathologic complete response data from Niagara! This study focuses on only comparing the cystectomy cohort. #AUA2025

Here is the disease-free survival, shown by pCR and non-pCR from Niagara. #AUA2025

🔬Not just mutations. 🧬Not just methylation. The new frontier in early cancer detection? The cfDNA fragmentome—size, shape, structure, and silence. nature International Society of Liquid Biopsy OncoAlert doi.org/10.1038/s41568…

🚨 New Uromigos episode alert! Dr. Mark Tyson from the Mayo Clinic joins Brian Rini, MD Tom Powles to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC. 🎙️ GU Oncology Now: buff.ly/kRshgKl 🍎 Apple Podcasts: buff.ly/wKcpg2D

May is #bladdercancer awareness month Bladder Cancer Advocacy Network Weill Cornell Medicine NewYork-Presbyterian

Thanks UroToday.com grateful to work w Sam S. Chang MD, MBA, future is bright for patients as we incorporate highly effective ADC/IO combinations, sensitive and predictive biomarkers, novel intravesical tx leading to bladder preservation for more patients Bladder Cancer Advocacy Network

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network

Big news in bladder cancer. R3 (n=480) of Disitimab Vedotin(HER2ADC) + Tori (PD1) vs chemo, hitting PFS + OS in 1st line irrespective of HER2 . “This reshapes the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo remegen.com/index.php?v=sh…

Unfortunate news for Joe Biden but I have confidence in his oncology team to get him into remission. Many contemporary advances in HSPC and CRPC, thanks to #cancermoonshot 🚀

🚨 Practice-changing data at #ASCO25! Maintenance lurbinectedin + atezolizumab significantly improves OS and PFS in ES-SCLC, per phase 3 IMforte study. 📌 A new standard may be emerging in a setting long starved for progress. Proud to highlight this as an #ASCO25 Featured Voice.

Renal cancer #ASCO25 1) Casdatifan/carbo phase 2 data (RR=41%) ⏩️ R3 PEAK1 2)Biomarkers from sequential tissue from adjuvant atezo study IM010 3) CAR-T (CD70) data cRR20% 4) Final analysis for ipi/nivo ITT (HR 0.71) 5) predicting response to Cabo/nivo from TME & Microbiome

Bladder cancer #ASCO25 1) Ipi/nivo vs 1st line chemo (HR 0.79)-near miss 2) maintenance SG/PD-L1 vs PD-L1 (PFS HR0.49)-still relevant? 3) CIS subset analysis for salanlimab in NMIBC-pt selection for therapy? 4) A new Nectin4 ADC 9MW/PD1 in phase II RR=88%! 5) EVP update on RR/tox

#ASCO25 preview SURE-02: In chemo-ineligible/refusing MIBC, neoadj SG+pembro led to 38.7% cCR (evaluable pts), bladder-sparing option. Well tolerated. cCR linked to luminal subtype & low stroma. Supports ADC+IO and biomarker-driven bladder preservation. Andrea Necchi Uromigos

Great work Philip Papayanis and Cherry Au highlighting full use of precision oncology, BRAFV600E widely metastatic CUP, +CD274, ipi/nivo with durable CR, ctDNA clearance BMJCaseReports Rush University System for Health Vanderbilt University Medical Center Vanderbilt Health Natera casereports.bmj.com/content/18/5/e…

2 days to #ASCO25 🎉 Back this year ➡️ download the @asco app to build your own agenda 5/30 IMG Oncologists 5/31 ASCO OncMedEdCoP Rapid UC/RCC Innovations in MedEd 6/1 PD breakfast Oral RCC/UC Plenary Rapid PCa 6/2 GU Posters Med Ed Orals 6/3 Oral PCa

🗣️Kidney Cancer Rapid Oral Abstracts #ASCO25 👉Abs4516: Dr Tian Zhang, MD, MHS presenting Step 1⃣ #PDIGREE Nivo/Ipi -> (SD/PR) Nivo vs Nivo/Cabo #ALLIANCE 🩺Clinical implications: - Step 1⃣ 33% stopped tx due to AEs (44%), PD (13%) - Step 2⃣ 67% pts registered PD (18.9%), SD/PR

Dr. Sheng presenting novel nectin-4 ADC Bulumtatug Fuvedotin (BFv) w/ MMAE payload + PD1 Toripalimab 🌟 Impressive confirmed ORR of 80% 🔻inc LFT, rash, hypoasthesia, asthenia ➡️ Phase 3 trial ongoing in China for pts with untreated mUC #ASCO25